What is the Origin of Senolytic Agent Intermittent Dosing?

The term is a direct clinical application of the discovery of senolytics, compounds that selectively target senescent cells, combined with the pharmacological principle of intermittent dosing to optimize therapeutic windows.

What is the Mechanism of Senolytic Agent Intermittent Dosing?

Senolytic agents typically function by disrupting the pro-survival pathways (e.g., Bcl-2 family proteins) that senescent cells employ to resist apoptosis. The intermittent schedule is essential because senescent cells, once cleared, require time to re-accumulate to a clinically significant level. This cyclical approach ensures that the therapeutic window exploits the difference in turnover rates between senescent and healthy cell populations, leading to a net reduction in the overall senescent cell burden and associated inflammation.

Senolytic Agent Intermittent Dosing ∞ Area

Senolytic Agent Intermittent Dosing

Meaning

The clinical strategy of administering senolytic agents, which are compounds designed to selectively induce apoptosis (programmed cell death) in senescent cells, in a periodic, non-continuous schedule. This intermittent dosing maximizes the clearance of detrimental senescent cells while minimizing potential systemic side effects and allowing for the natural turnover of healthy cells. It is a precision pharmacological approach to longevity.